Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 4/20 | 0.37 |
| ▸ | SELL | P14151 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20790015 | 0.87 | OPRL1 (0.36) | LMNAMEN1KMT2APDE4DPDE4A | |
| SCHEMBL20790295 | 0.82 | LMNA (0.40) | SELPSELLLMNAMEN1KMT2A | |
| SCHEMBL20790080 | 0.79 | MEN1 (0.44) | SELPSELLMEN1KMT2APTGDR2 | |
| SCHEMBL20819563 | 0.78 | HSD17B10 (0.32) | SELPSELLLMNAMEN1KMT2A | |
| SCHEMBL1735759 | 0.76 | CA12 (0.52) | LMNAKMT2AL3MBTL1 | |
| SCHEMBL20790112 | 0.75 | LMNA (0.39) | SELPSELLLMNAMEN1KMT2A | |
| SCHEMBL20819567 | 0.74 | PTGDR2 (0.40) | SELPSELLPTGDR2DRD4 | |
| SCHEMBL20819559 | 0.73 | SELP (0.34) | SELPSELLMEN1KMT2APTGDR2 | |
| SCHEMBL20819536 | 0.73 | CYP3A4 (0.36) | SELPSELLLMNAMEN1KMT2A | |
| SCHEMBL20790143 | 0.71 | PDE4B (0.48) | SELPSELLPDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865474-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2021-08-18 | — | — | EP | disclosed |
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2021-08-05 | — | — | US | disclosed |
| EP-3736270-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3736267-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-27 | — | — | US | disclosed |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-20 | — | — | US | disclosed |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| CN-111954664-A | Cystic fibrosis transmembrane conductance regulator and methods of use | 艾伯维海外有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3736267-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| EP-3736270-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| US-10829473-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-10 | — | — | US | disclosed |
| EP-3681864-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-10-28 | — | — | EP | disclosed |
| US-20200277276-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277273-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277275-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277274-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| EP-3681864-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019053634-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-20200277275-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-10829473-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-20200277276-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-20200277274-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-20200277273-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | SELP 2767/4885SELL 3785/4885LMNA 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.